---
title: "LIFETECH SCI announced the two-year follow-up results of the Phase II and Phase III clinical studies of the IBS® absorbable drug-eluting coronary stent system"
description: "LIFETECH SCI announced the two-year follow-up results of its IBS® absorbable drug-eluting coronary stent system from the Phase II and III clinical studies. The study showed that the late lumen loss in"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/263278292.md"
published_at: "2025-10-29T11:39:03.000Z"
---

# LIFETECH SCI announced the two-year follow-up results of the Phase II and Phase III clinical studies of the IBS® absorbable drug-eluting coronary stent system

> LIFETECH SCI announced the two-year follow-up results of its IBS® absorbable drug-eluting coronary stent system from the Phase II and III clinical studies. The study showed that the late lumen loss in the Phase II trial group was 0.28mm, compared to 0.23mm in the control group, achieving non-inferiority for the primary endpoint. In the Phase III study, the two-year target lesion failure (TLF) rate post-implantation was 5.5%, with only 5 cases of stent thrombosis occurring, resulting in a thrombosis event rate of 0.5%. This stent is the world's first fully biodegradable iron-based absorbable coronary stent, featuring good biocompatibility and ease of operation

According to the Zhitong Finance APP, LIFETECH SCI (01302) announced that the group's independently developed IBS® absorbable drug-eluting coronary stent system has successfully completed two years of follow-up for both Phase II and Phase III clinical studies. On October 26-27, 2025, local time in the United States, Professor Song Lei from Fuwai Hospital of the Chinese Academy of Medical Sciences, representing Academician Gao Runlin and all researchers, will present the two-year primary endpoint imaging follow-up results of the IBS® coronary stent Phase II clinical study and the two-year clinical endpoint follow-up results of the Phase III clinical study at the Transcatheter Cardiovascular Therapeutics Annual Meeting (TCT 2025).

The two-year follow-up results of the Phase II clinical study of the IBS® coronary stent showed that the late lumen loss in the lesion segment (experimental group: 0.28±0.52mm, control group: 0.23±0.43mm) achieved non-inferiority for the primary endpoint. No stent thrombosis events occurred in the experimental group, while one stent thrombosis event occurred in the control group.

The two-year clinical follow-up results of the Phase III clinical study of the IBS® coronary stent showed that the target lesion failure (TLF) rate was 5.5% two years after the implantation of the IBS® coronary stent. Only five stent thrombosis events occurred within two years, with an event rate of only 0.5%. Among these, four occurred within one month, and three were clearly due to non-device-related reasons.

To the company's knowledge, the IBS® coronary stent is the world's first fully biodegradable iron-based absorbable coronary stent. Its matrix is made from high-purity nitrogen-doped iron tubes with high strength and high plasticity, resulting in a thin-walled stent with strong support. Innovative material research and a unique technical pathway allow this product to retain the advantages of permanent metal coronary stents, such as a complete range of specifications, superior physical properties, good biocompatibility, and ease of operation, while also possessing the characteristic of complete absorbability, effectively avoiding a series of long-term prognostic issues that may arise from the implantation of permanent metal stents.

The announcement of the two-year follow-up results of the Phase II and Phase III clinical studies of the IBS® coronary stent further strengthens the evidence-based medical evidence for this innovative product. Currently, the clinical study follow-up data of the IBS® coronary stent has been submitted to the National Medical Products Administration and EU CE registration approval, and it is expected to bring an unprecedented, safe, and effective treatment method for global coronary heart disease patients in the near future, laying a solid foundation for the global development of other core products on the company's iron-based biodegradable materials platform

### Related Stocks

- [01302.HK - LIFETECH SCI](https://longbridge.com/en/quote/01302.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 先健科技向香港交易所提交了董事名單 | 先健科技已向香港證券交易所提交了更新的董事名單。董事會包括執行董事謝躍輝（董事長兼首席執行官）、劉建雄（首席財務官）、吳麗平、方宇和馮曉玲。姜峯為非執行董事，而周魯明和陳冬霞則擔任獨立非執行董事。委員會成員資格已披露，陳冬霞擔任審計委員會和 | [Link](https://longbridge.com/en/news/273687357.md) |
| 石四藥 (2005) 發盈警料去年盈利倒退 45 至 60% | 石四藥集團發盈警，預期截至去年底止年度股東應佔溢利按年下跌 45 至 60%；2024 年度錄得股東應佔溢利 10.61 億港元。 | [Link](https://longbridge.com/en/news/276431030.md) |
| 宇樹人形機器人搭載禾賽激光雷達 春晚效應推升股價 | 宇樹科技的兩款人形機器人在央視春晚表演中搭載禾賽 JT128 雷射雷達，展現出高水平的協同動作。受此影響，禾賽（HSAI）股價在美股市場上漲，週二最高達到 28.21 美元，收盤時為 26.77 美元，漲幅近 4%。禾賽 JT 系列雷射雷達 | [Link](https://longbridge.com/en/news/276198028.md) |
| 10:15 ETInventHelp 的發明者開發了一款適合 AFO 支架的牛仔靴（AFD-123） | InventHelp 開發了一款新的牛仔靴設計，名為 TRESTONS'S BOOT，專為佩戴 AFO 支架的個人設計。該靴子旨在提升舒適度、支撐力和風格，同時隱藏矯形器具，為穿戴者提供一種正常的感覺。該設計易於穿着，目前可供製造商許可或銷 | [Link](https://longbridge.com/en/news/276065425.md) |
| 根據 MarketsandMarkets™的報告，外圍血管設備市場預計到 2031 年將達到 132.2 億美元 | 外周血管設備市場預計將從 2026 年的 100.2 億美元增長到 2031 年的 132.2 億美元，年均增長率為 5.7%。主要驅動因素包括外周動脈疾病（PAD）的發病率上升以及微創手術技術的進步。 angioplasty 支架細分市場 | [Link](https://longbridge.com/en/news/276066104.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.